+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

The Pharmaceutical Market: Norway

  • ID: 3232896
  • Report
  • April 2015
  • Region: Norway
  • 67 Pages
  • Frost & Sullivan
1 of 2
Overview Of The Pharmaceutical Market In Norway:

The macroenvironment for the Norwegian pharmaceutical industry is improving. Politically, the centre-left coalition is expected to hold together at least until the general election but the risk of the coalition breaking up has grown. Economically, the recession was far less pronounced in Norway than in most other European countries and economic recovery is now strengthening. Legally, laws on intellectual property and patent provision are in line with WTO/TRIPS regulations. However, Norway remains on the USTR’s Watch List for concerns over patent protection. Demographically, the population is ageing, increasing demand for pharmaceuticals in the near term.

The introduction of international reference pricing has had a moderating effect on Norwegian pharmaceutical price levels, and a step-price system for off-patent drugs has ensured that prices for all generics have fallen. Important steps towards cost-containment have also been taken for reimbursable pharmaceuticals, including the use of a first-choice system. A report by the Business Research Foundation (SNF) has shown that Norwegian pharmaceutical prices are among the lowest in Western Europe. Therefore, market growth is a result of increased consumption, largely due to the ageing population and the introduction of new drugs on the market. Norway is receptive to new drugs, as long as they are cost-effective and have proven therapeutic benefits.

Although Norway is not part of the European Union, the process for pharmaceutical registration has been aligned to EU regulations. The regulatory reforms made the centralised procedure mandatory for all new active substances, and all drugs in a number of drug categories, including all biotech products. PCI Biotech reported that it had been awarded a BIA grant from the Research Council of Norway for the project immunological effects of photochemical internalisation local treatment of cancer with metastasis.

Competitive Landscape:

The competitive landscape section provides comparative company analyses and rankings by US$ sales and % share of total sales - for the total pharmaceutical sector, as well as the OTC, generics, and distribution sub-sectors.

Note: Product cover images may vary from those shown
2 of 2
1. SWOT

2. Political

3. Economic

4. Business Environment

5. Industry Forecast

6. Pharmaceutical Market Forecast
  • Table: Pharmaceutical Sales, Historical Data And Forecasts (Norway 2010-2018)
7. Healthcare Market Forecast
  • Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Norway 2010-2018)
  • Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Norway 2010-2018)
  • Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Norway 2010-2018)
8. Norway

9. Pharmaceutical Trade Forecast
  • Table: Pharmaceutical Trade Data And Forecasts (Norway 2012-2018)
  • Table: Pharmaceutical Trade Data And Forecasts local currency (Norway 2012-2018)
10. Macroeconomic Forecasts

11. Economic Analysis
  • Table: GDP Contribution To Growth (Norway 2011-2018)
  • Table: Long-Term Macroeconomic Forecasts (Norway 2014-2023)
12. Industry Risk Reward Ratings

13. Western Europe Risk/Reward Ratings

14. Norway Risk/Reward Ratings

15. Rewards

16. Risks

17. Market Overview

18. Industry Trends And Developments

19. Epidemiology

20. Healthcare Sector

21. Clinical Trials

22. Regulatory Development

23. Pricing Regime

24. Reimbursement Regime

25. Competitive Landscape
  • Table: The Top 25 Pharmaceutical Companies In Norway
26. Demographic Forecast
  • Table: Norway's Population By Age Group, 1990-2020 ('000)
  • Table: Norway's Population By Age Group, 1990-2020 (% of total)
  • Table: Norway's Key Population Ratios, 1990-2020
  • Table: Norway's Rural And Urban Population, 1990-2020
27. Glossary

28. Methodology

29. Pharmaceutical Expenditure Forecast Model

30. Healthcare Expenditure Forecast Model

31. Notes On Methodology

32. Risk/Reward Ratings Methodology

33. Ratings Overview
  • Table: Pharmaceutical Risk/Reward Ratings Indicators
34. Indicator Weightings
Note: Product cover images may vary from those shown
3 of 2

Loading
LOADING...

Adroll
adroll